招股书显示，博迈医疗专注于高性能血管介入医疗器械的研发、生产及全球销售，是全球行业内技术及 产品领先的复杂血管疾病介入治疗解决方案提供商，同时也是国产血管介入球囊导管领域产销量领先的 研发生产企业。 此次创业板IPO，博迈医疗拟募集资金17亿元，投向松山湖全球总部项目、湖南生产基地技改（一期） 项目、介入类医疗器械研发项目等5个项目。 北京商报讯（记者 丁宁）深交所官网显示，广东博迈医疗科技股份有限公司（以下简称"博迈医疗"） 创业板IPO进入已问询阶段。 ...

在研发与生产布局方面，公司重视全球资源整合与产能保障，目前已在全球范围内设立5个研发中心及实验 室，持续推动核心技术迭代与创新产品研发;建立4个生产基地，确保产品规模化、高质量供应;同时搭建3个 国际运营中心，为全球市场拓展提供高效的运营支持与服务保障。 在市场覆盖维度方面，公司产品已成功行销海内外超100个国家和地区，服务于全球上万家医院及医疗中 心，凭借稳定的产品性能、成体系的治疗解决方案及专业的技术支持，在国内外血管介入医疗器械市场树 立了良好的品牌形象，逐步构建起全球化的市场布局与客户服务网络。 公司长期践行"创新+规模化+国际化"三位一体经营发展战略，已成长为全球血管介入产业领域高速发展、 具备重要行业影响力的跨国型平台企业，"助力中国原创、造福全球患者"亦是公司科技创新与全球产业化 的核心发展理念。自创立以来，公司持续保持高强度研发投入，构建完善高效的研发人才团队与IPD产品研 发体系，依托广东省血管介入治疗技术及器械工程技术研究中心、东莞市血管介入医疗器械研究开发重点 实验室、CNAS实验室等核心科研载体，通过全球范围的产学研合作与医工创新合作，在产品技术、核心工 艺等领域取得多项全球性突破。截 ...

Group 1: New Listings - Jiangsu Xihua New Energy Technology Co., Ltd. listed on the Shanghai Stock Exchange main board on December 23, raising 1.01 billion yuan, with a first-day stock price increase of 264.46% and a market cap of approximately 11.4 billion yuan as of December 29 [3][5] - Ningbo Jianxin Superconducting Technology Co., Ltd. listed on the Shanghai Stock Exchange Sci-Tech Innovation Board on December 24, raising 779 million yuan, with a first-day stock price increase of 212.81% and a market cap of approximately 7.9 billion yuan as of December 29 [3][5] - Shenzhen Tian Su Measurement and Testing Co., Ltd. listed on the Shenzhen Stock Exchange ChiNext on December 23, raising 600 million yuan, with a first-day stock price increase of 174.48% and a market cap of approximately 6.8 billion yuan as of December 29 [4][5] - Nabai Chuan New Energy Co., Ltd. also listed on the Shenzhen Stock Exchange ChiNext on December 23, raising 632 million yuan, with a first-day stock price increase of 408.17% and a market cap of approximately 10.1 billion yuan as of December 29 [4][5] Group 2: Companies Passing Review - Shijiazhuang Vision Technology Co., Ltd. passed the review for listing on the Shanghai Stock Exchange Sci-Tech Innovation Board on December 24, focusing on micro-display solutions [6][8] - Luoyang Shenglong Mining Group Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange main board on December 23, engaged in non-ferrous metal mining [9][10] - Hangzhou Fuen Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange main board on December 26, specializing in eco-friendly fabric [9][10] - Shenzhen Dapu Microelectronics Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange ChiNext on December 25, focusing on enterprise-level SSD products [9][10] - Nanchang Sanrui Intelligent Technology Co., Ltd. passed the review for listing on the Shenzhen Stock Exchange ChiNext on December 26, specializing in drone and robot power systems [9][10] Group 3: Companies Submitting IPO Applications - Tianjin Fujida Bicycle Industrial Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange main board on December 24, planning to raise 773 million yuan [12][14] - Shenyang Compressor Group Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange main board on December 25, planning to raise 2.134 billion yuan [12][19] - Shenzhen Hanno Medical Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 23, planning to raise 1.062 billion yuan [12][23] - Dandong Oriental Measurement and Control Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 25, planning to raise 1.1 billion yuan [12][25] - Suzhou Tongxin Medical Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 26, planning to raise 1.064 billion yuan [12][27] - Shenzhen Deep Blue Ocean Technology Co., Ltd. submitted an IPO application to the Shanghai Stock Exchange Sci-Tech Innovation Board on December 26, planning to raise 1.5 billion yuan [12][29] Group 4: Financial Data Highlights - Fujida projected revenues of 4.371 billion yuan, 3.621 billion yuan, and 4.880 billion yuan from 2022 to 2024, with net profits of 348 million yuan, 285 million yuan, and 408 million yuan respectively [17][18] - Shenyang Compressor Group projected revenues of 7.396 billion yuan, 8.206 billion yuan, and 9.309 billion yuan from 2022 to 2024, with net profits of 181 million yuan, 355 million yuan, and 442 million yuan respectively [20][21] - Hanno Medical projected revenues of 0, 298 million yuan, and 493 million yuan from 2022 to 2024, with net losses of 647 million yuan, 3.41 billion yuan, and 1.83 billion yuan respectively [24] - Oriental Measurement and Control projected revenues of 603 million yuan, 521 million yuan, and 567 million yuan from 2022 to 2024, with net profits of 92.5 million yuan, 74.8 million yuan, and 73.1 million yuan respectively [26] - Tongxin Medical projected revenues of 8.611 million yuan, 50.453 million yuan, and 77.351 million yuan from 2022 to 2024, with net losses of 1.89 billion yuan, 3.06 billion yuan, and 3.72 billion yuan respectively [28]

深圳商报·读创客户端记者 宁可坚 深交所官网显示，12月24日，广东博迈医疗科技股份有限公司（简称"博迈医疗"）创业板IPO获受理。 根据招股书，博迈医疗专注于高性能血管介入医疗器械的研发、生产及全球销售，是全球行业内技术及 产品领先的复杂血管疾病介入治疗解决方案提供商，同时也是国产血管介入球囊导管领域产销量领先的 研发生产企业。 根据2025年6月颁布的《关于执行京津冀"3+N"联盟起搏器、冠脉药物球囊等五类医用耗材集中带量采 购第三年协议期有关工作的通知》，此次集采涵盖冠脉药物球囊、心脏起搏器、冠脉扩张球囊、导引导 管和导引导丝五类心血管耗材，广泛用于冠心病、心律失常等治疗。通过"以量换价"，整体价格降幅超 50%，部分单品降幅达70%。 博迈医疗此次IPO拟募集资金17亿元，主要用于松山湖全球总部项目、湖南生产基地技改（一期）项 目、介入类医疗器械研发项目、营销网络建设项目和补充流动资金。 | 序号 | 项目名称 | 投资总额 | 拟使用募集资金 | | --- | --- | --- | --- | | 1 | 松山湖全球总部项目 | 94,568.54 | 90,000.00 | | 2 | 湖南生 ...

12月24日，深交所官网显示，广东博迈医疗科技股份有限公司（简称"博迈医疗"）、中电科思仪科技股 份有限公司（简称"思仪科技"）创业板IPO获受理；上交所官网显示，天津富士达自行车工业股份有限 公司（简称"富士达"）主板IPO申请获受理，三家公司累计募资约39.73亿元。 | 项目动态列表 | | | | | 글 글 목 | | --- | --- | --- | --- | --- | --- | | 序号 发行人全称 板块 | 审核状态 注册地 证监会行业 保存机构 | | 律师事务所 | 会计师事务所 | 更新日期 娶理日期 | | 中电科思仪科技股份有 创业板 限公司 | 日前 山东 仪器仪表制造 32 | 国泰海通 | 上海市锦天城律 障 移所 | 容诚会计师事务 所(特殊管通合 | 2025-12-24 2025-12-24 | | | | | | 伏) | | | 2 广东博迈医疗科技股份 创业板 有限公司 | 已受理 专用设备制造 厂乐 Al | 中含公司 | 北京国权律师事 好所 | 容域会计师事务 所(特殊普通合 | 2025-12-24 2025-12-24 | | | | | | 伙) ...